JP2017528510A - 自己免疫疾患の処置に有用な置換ピリミジン誘導体 - Google Patents
自己免疫疾患の処置に有用な置換ピリミジン誘導体 Download PDFInfo
- Publication number
- JP2017528510A JP2017528510A JP2017516829A JP2017516829A JP2017528510A JP 2017528510 A JP2017528510 A JP 2017528510A JP 2017516829 A JP2017516829 A JP 2017516829A JP 2017516829 A JP2017516829 A JP 2017516829A JP 2017528510 A JP2017528510 A JP 2017528510A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- alkyl
- phenyl
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 27
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 9
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title description 2
- 150000003230 pyrimidines Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 74
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 22
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 13
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 9
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 27
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 15
- -1 6 -phenyl Phenyl Chemical group 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000012453 solvate Substances 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- RRFYNZOHHNEHCG-HCWXCVPCSA-N (1R,2S,5S)-5-methylcyclopent-3-ene-1,2-diol Chemical compound C[C@H]1C=C[C@@H]([C@@H]1O)O RRFYNZOHHNEHCG-HCWXCVPCSA-N 0.000 claims description 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 229910052727 yttrium Inorganic materials 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 239000000725 suspension Substances 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 239000000843 powder Substances 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000010408 film Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 108020004566 Transfer RNA Proteins 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 229920000858 Cyclodextrin Polymers 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 208000033068 episodic angioedema with eosinophilia Diseases 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 108090000467 Interferon-beta Proteins 0.000 description 4
- 102000003996 Interferon-beta Human genes 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 4
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- RJOJHKXZYVLLKN-UHFFFAOYSA-N 2-chloro-3-oxopropanenitrile Chemical compound O=CC(Cl)C#N RJOJHKXZYVLLKN-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 0 CC(**)=CC1=C(C(*)=*)C(C*(*)*)=C*1 Chemical compound CC(**)=CC1=C(C(*)=*)C(C*(*)*)=C*1 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 3
- 108010072051 Glatiramer Acetate Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 3
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 229960000623 carbamazepine Drugs 0.000 description 3
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- 229960001156 mitoxantrone Drugs 0.000 description 3
- 150000004682 monohydrates Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229940072228 neurontin Drugs 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- WYROLENTHWJFLR-ACLDMZEESA-N queuine Chemical compound C1=2C(=O)NC(N)=NC=2NC=C1CN[C@H]1C=C[C@H](O)[C@@H]1O WYROLENTHWJFLR-ACLDMZEESA-N 0.000 description 3
- 102000005499 queuine tRNA-ribosyltransferase Human genes 0.000 description 3
- 108010061997 queuine tRNA-ribosyltransferase Proteins 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 229940090016 tegretol Drugs 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- QLUKFGWGULAPOA-UHFFFAOYSA-N (2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)methyl-(3-phenylpropyl)azanium chloride Chemical compound [Cl-].NC=1NC(C2=C(N=1)NC=C2C[NH2+]CCCC1=CC=CC=C1)=O QLUKFGWGULAPOA-UHFFFAOYSA-N 0.000 description 2
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 2
- LYUQWQRTDLVQGA-UHFFFAOYSA-N 3-phenylpropylamine Chemical compound NCCCC1=CC=CC=C1 LYUQWQRTDLVQGA-UHFFFAOYSA-N 0.000 description 2
- FMKSMYDYKXQYRV-UHFFFAOYSA-N 7-cyano-7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1C(C#N)=CN2 FMKSMYDYKXQYRV-UHFFFAOYSA-N 0.000 description 2
- KFYRPLNVJVHZGT-UHFFFAOYSA-N Amitriptyline hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KFYRPLNVJVHZGT-UHFFFAOYSA-N 0.000 description 2
- 108030001720 Bontoxilysin Proteins 0.000 description 2
- UIUWUSWXMXWDKE-UHFFFAOYSA-N C1(=CC=CC=C1)CCCNCC1=CNC=2N=C(NC(C=21)=O)NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound C1(=CC=CC=C1)CCCNCC1=CNC=2N=C(NC(C=21)=O)NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 UIUWUSWXMXWDKE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- OLAFFPNXVJANFR-UHFFFAOYSA-N DG Chemical compound N1C(N)=NC(=O)C2=C1NC=C2 OLAFFPNXVJANFR-UHFFFAOYSA-N 0.000 description 2
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 2
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 108010005716 Interferon beta-1a Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- FNSKZLZQTSLPII-UHFFFAOYSA-N N-[5-[(dibenzylamino)methyl]-4-oxopyrrolo[2,3-d]pyrimidin-2-yl]octanamide Chemical compound C1=NC2=NC(NC(=O)CCCCCCC)=NC(=O)C2=C1CN(CC=1C=CC=CC=1)CC1=CC=CC=C1 FNSKZLZQTSLPII-UHFFFAOYSA-N 0.000 description 2
- QTGLWFKIQNMKNA-UHFFFAOYSA-N O=C1C2=C(N=C(N1)NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)NC=C2CNC=O Chemical compound O=C1C2=C(N=C(N1)NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)NC=C2CNC=O QTGLWFKIQNMKNA-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- WFVQWHZNWDTIBM-UHFFFAOYSA-N [Cl-].NC=1NC(C2=C(N=1)NC=C2C[NH2+]CCCC)=O Chemical compound [Cl-].NC=1NC(C2=C(N=1)NC=C2C[NH2+]CCCC)=O WFVQWHZNWDTIBM-UHFFFAOYSA-N 0.000 description 2
- NGPCMQWHWPUZKG-UHFFFAOYSA-N [Cl-].NC=1NC(C2=C(N=1)NC=C2C[NH2+]CCCCCC)=O Chemical compound [Cl-].NC=1NC(C2=C(N=1)NC=C2C[NH2+]CCCCCC)=O NGPCMQWHWPUZKG-UHFFFAOYSA-N 0.000 description 2
- MLSVJHOYXJGGTR-IFHOVBQLSA-N acetic acid;(2s)-n-[(2r)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4r,7s,10s,13s,16s)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,1 Chemical compound CC(O)=O.C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 MLSVJHOYXJGGTR-IFHOVBQLSA-N 0.000 description 2
- WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 2
- 125000006242 amine protecting group Chemical group 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 229960000836 amitriptyline Drugs 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940053031 botulinum toxin Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940038717 copaxone Drugs 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960000556 fingolimod Drugs 0.000 description 2
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229960004801 imipramine Drugs 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000010902 jet-milling Methods 0.000 description 2
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229940009697 lyrica Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- MDPAHULGZSCHOW-UHFFFAOYSA-N n-(4-oxopyrrolo[2,3-d]pyrimidin-2-yl)octanamide Chemical compound CCCCCCCC(=O)NC1=NC(=O)C2=CC=NC2=N1 MDPAHULGZSCHOW-UHFFFAOYSA-N 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229960002036 phenytoin Drugs 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 229960001233 pregabalin Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- XVIAPHVAGFEFFN-UHFFFAOYSA-N pyrimidine-5-carbonitrile Chemical compound N#CC1=CN=CN=C1 XVIAPHVAGFEFFN-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 description 2
- 229940041597 tofranil Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- TWHNMSJGYKMTRB-KXYUELECSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;2-[(1r)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 TWHNMSJGYKMTRB-KXYUELECSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 description 1
- PJRSUKFWFKUDTH-JWDJOUOUSA-N (2s)-6-amino-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]propanoyl]amino]acetyl]amino]propanoyl Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(N)=O PJRSUKFWFKUDTH-JWDJOUOUSA-N 0.000 description 1
- SSNHGLKFJISNTR-DYSNNVSPSA-N (6ar,10ar)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol;2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1.C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 SSNHGLKFJISNTR-DYSNNVSPSA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SWELIMKTDYHAOY-UHFFFAOYSA-N 2,4-diamino-6-hydroxypyrimidine Chemical compound NC1=CC(=O)N=C(N)N1 SWELIMKTDYHAOY-UHFFFAOYSA-N 0.000 description 1
- QTUKEYORKMKFGQ-UHFFFAOYSA-N 2-amino-5-(butylaminomethyl)-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one Chemical compound NC=1NC(C2=C(N=1)NC=C2CNCCCC)=O QTUKEYORKMKFGQ-UHFFFAOYSA-N 0.000 description 1
- HLKFXDKKWJAVIC-UHFFFAOYSA-N 2-amino-5-[(3-phenylpropylamino)methyl]pyrrolo[2,3-d]pyrimidin-4-one Chemical compound NC1=NC(C=2C(=N1)N=CC=2CNCCCC1=CC=CC=C1)=O HLKFXDKKWJAVIC-UHFFFAOYSA-N 0.000 description 1
- IICSETALMGPWSQ-UHFFFAOYSA-N 2-amino-5-[(hexylamino)methyl]-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one Chemical compound NC=1NC(C2=C(N=1)NC=C2CNCCCCCC)=O IICSETALMGPWSQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- CIOBFBYUHYKBBM-UHFFFAOYSA-N 4-oxo-2-(tritylamino)-1,7-dihydropyrrolo[2,3-d]pyrimidine-5-carbaldehyde Chemical compound N1C(=O)C=2C(C=O)=CNC=2N=C1NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 CIOBFBYUHYKBBM-UHFFFAOYSA-N 0.000 description 1
- PVKLTVXESOEKJR-UHFFFAOYSA-N 4-oxo-2-(tritylamino)-1,7-dihydropyrrolo[2,3-d]pyrimidine-5-carbonitrile Chemical compound N1C=2NC=C(C#N)C=2C(=O)N=C1NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 PVKLTVXESOEKJR-UHFFFAOYSA-N 0.000 description 1
- VULZYZZVQJHMEN-UHFFFAOYSA-N 5-(butylaminomethyl)-2-(tritylamino)-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one Chemical compound C(CCC)NCC1=CNC=2N=C(NC(C=21)=O)NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 VULZYZZVQJHMEN-UHFFFAOYSA-N 0.000 description 1
- WJLDUJJCWWZTBX-UHFFFAOYSA-N 5-[(butan-2-ylamino)methyl]-2-(tritylamino)-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one Chemical compound CCC(C)NCC1=CNC=2N=C(NC(C=21)=O)NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 WJLDUJJCWWZTBX-UHFFFAOYSA-N 0.000 description 1
- HDLOXKRYJGJFMQ-UHFFFAOYSA-N 5-[(hexan-3-ylamino)methyl]-2-(tritylamino)-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one Chemical compound CCC(CCC)NCC1=CNC=2N=C(NC(C=21)=O)NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 HDLOXKRYJGJFMQ-UHFFFAOYSA-N 0.000 description 1
- FEBPXALEDSBDJU-UHFFFAOYSA-N 5-[(hexylamino)methyl]-2-(tritylamino)-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one Chemical compound C(CCCCC)NCC1=CNC=2N=C(NC(C=21)=O)NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 FEBPXALEDSBDJU-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 229940124292 CD20 monoclonal antibody Drugs 0.000 description 1
- 229940124296 CD52 monoclonal antibody Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- MGARBPBWMBWFJX-UHFFFAOYSA-N NC(N1)=NC(NC=C2CNCCCC3=CC=CC=C3)=C2C1=O.NC(N1)=NC(NC=C2CNCCCC3=CC=CC=C3)=C2C1=O Chemical compound NC(N1)=NC(NC=C2CNCCCC3=CC=CC=C3)=C2C1=O.NC(N1)=NC(NC=C2CNCCCC3=CC=CC=C3)=C2C1=O MGARBPBWMBWFJX-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- WYROLENTHWJFLR-UHFFFAOYSA-N Queuine Natural products C=1NC=2NC(N)=NC(=O)C=2C=1CNC1C=CC(O)C1O WYROLENTHWJFLR-UHFFFAOYSA-N 0.000 description 1
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Natural products CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 206010071436 Systolic dysfunction Diseases 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229940057415 aubagio Drugs 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- CELPHAGZKFMOMR-UHFFFAOYSA-N azanium;dichloromethane;methanol;hydroxide Chemical compound [NH4+].[OH-].OC.ClCCl CELPHAGZKFMOMR-UHFFFAOYSA-N 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 1
- 229950011318 cannabidiol Drugs 0.000 description 1
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940015688 caverject Drugs 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 229940119321 dantrium Drugs 0.000 description 1
- LTWQNYPDAUSXBC-CDJGKPBYSA-L dantrolene sodium hemiheptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N\N1C(=O)[N-]C(=O)C1.C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N\N1C(=O)[N-]C(=O)C1 LTWQNYPDAUSXBC-CDJGKPBYSA-L 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 229960004419 dimethyl fumarate Drugs 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940099170 ditropan Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 238000007345 electrophilic aromatic substitution reaction Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940042385 glatiramer Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000010726 hind limb paralysis Diseases 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940124625 intravenous corticosteroids Drugs 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940072170 lamictal Drugs 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940097443 levitra Drugs 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 208000027905 limb weakness Diseases 0.000 description 1
- 231100000861 limb weakness Toxicity 0.000 description 1
- 229940063721 lioresal Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- GRWIABMEEKERFV-UHFFFAOYSA-N methanol;oxolane Chemical compound OC.C1CCOC1 GRWIABMEEKERFV-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000013580 millipore water Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 229960001165 modafinil Drugs 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940028444 muse Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- MRUNQKQTAMUPRF-PUTLROBFSA-N nuedexta Chemical compound Br.OS(O)(=O)=O.C([C@@H]12)CCC[C@]11CCN(C)[C@H]2CC2=CC=C(OC)C=C21.C1C([C@H](C2)C=C)CCN2[C@H]1[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21.C1C([C@H](C2)C=C)CCN2[C@H]1[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 MRUNQKQTAMUPRF-PUTLROBFSA-N 0.000 description 1
- 229940037869 nuedexta Drugs 0.000 description 1
- 229950005751 ocrelizumab Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- REEZZSHJLXOIHL-UHFFFAOYSA-N octanoyl chloride Chemical compound CCCCCCCC(Cl)=O REEZZSHJLXOIHL-UHFFFAOYSA-N 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229960001816 oxcarbazepine Drugs 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 108010021753 peptide-Gly-Leu-amide Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940117394 provigil Drugs 0.000 description 1
- 229940035613 prozac Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940038850 rebif Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000011519 second-line treatment Methods 0.000 description 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 229960002639 sildenafil citrate Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 229940121136 tecfidera Drugs 0.000 description 1
- 229960000331 teriflunomide Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000488 tizanidine Drugs 0.000 description 1
- 229960004045 tolterodine Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 229940061414 trileptal Drugs 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 235000019583 umami taste Nutrition 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229940072690 valium Drugs 0.000 description 1
- 229960002381 vardenafil Drugs 0.000 description 1
- 229940094720 viagra Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 229940000119 zanaflex Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
・βインターフェロン1a(Avonex)
・βインターフェロン1a(Rebif)
・βインターフェロン1b(Betaferon)
・グラチラマー酢酸塩(Copaxone)
・Natalizumabは、第一選択薬よりも再発率を低下させる;しかし、進行性多巣性白質脳症のような副作用の問題のために、これは、他の処置法に反応しない患者か、又は重症疾患の患者のために確保される第二選択薬である。
・Fingolimod(Gilenya)−急速に進行する重症再発寛解型MS(1年に2回以上の再発)の患者のために、そしてβインターフェロン剤の1つでの処置にもかかわらずMSが活動性を維持している患者の第二選択治療薬として、2011年3月に認可された。
・フマル酸ジメチル(Tecfidera)は、2013年にFDAから認可を受けたもので、再発寛解型MSの成人用の経口第一選択治療薬である。
・Teriflunomide(Aubagio)は、2012年9月にFDAの承認を受けたもので、再発型MSの処置用の経口投与可能な免疫調節薬である。
・Mitoxantroneは、その使用が、重度の副作用、収縮機能不全、不妊症、及び急性骨髄性白血病により制限されるが、他の医薬品に反応しない患者の第三選択肢である。
本発明は、自己免疫症状、特に多発性硬化症の処置のための新規な医薬品を提供する。本発明の1つの実施態様は、式(I):
で示される化合物、並びにその薬学的に許容し得る塩及び溶媒和物[式中、
R1は、H及びCH3から選択され、
R2は、H、C4H9アルキル、C6H13アルキル及びC3H6−フェニル(該フェニルは、場合によりOH又はOCH3によって置換されている)から選択され、
Xは、O又はSであり、
Yは、C、N又はSである]を記述する。
好ましい実施態様において、R1はHである。
好ましい実施態様において、R2は、C4H9アルキル、C6H13アルキル及びC3H6−フェニルから選択される。
特に好ましい実施態様において、R2はC3H6−フェニルである。
好ましい実施態様において、XはOである。
好ましい実施態様において、Yは、C又はNである。
特に好ましい実施態様において、YはNである。
XがOであり、
YがNであり、
R1がHであり;そして
R2が、C4H9アルキル、C6H13アルキル及びC3H6−フェニルから選択される、式(I)の化合物である。
特に好ましい実施態様において、R2はC3H6−フェニルである。
2−アミノ−5−((ブチルアミノ)メチル)−3,7−ジヒドロ−4H−ピロロ[2,3−d]ピリミジン−4−オン、
塩化N−((2−アミノ−4−オキソ−4,7−ジヒドロ−3H−ピロロ[2,3−d]ピリミジン−5−イル)メチル)ブタン−1−アミニウム、
2−アミノ−5−((ヘキシルアミノ)メチル)−3,7−ジヒドロ−4H−ピロロ[2,3−d]ピリミジン−4−オン、
塩化N−((2−アミノ−4−オキソ−4,7−ジヒドロ−3H−ピロロ[2,3−d]ピリミジン−5−イル)メチル)ヘキサン−1−アミニウム、
キューイン(Queuine);2−アミノ−5−((((1S,4S,5R)−4,5−ジヒドロキシシクロペンタ−2−エン−1−イル)アミノ)メチル)−3,7−ジヒドロ−4H−ピロロ[2,3−d]ピリミジン−4−オン、
キューインHCl;2−アミノ−5−[[[(1S,4S,5R)−4,5−ジヒドロキシ−2−シクロペンテン−1−イル]アミノ]メチル]−1,7−ジヒドロ−4H−ピロロ[2,3−d]ピリミジン−4−オン、一塩酸塩。
2−アミノ−5−(((3−フェニルプロピル)アミノ)メチル)−3,7−ジヒドロ−4H−ピロロ[2,3−d]ピリミジン−4−オン
塩化N−((2−アミノ−4−オキソ−4,7−ジヒドロ−3H−ピロロ[2,3−d]ピリミジン−5−イル)メチル)−3−フェニルプロパン−1−アミニウム。
[式中、
R1は、H及びCH3から選択され、
R2は、H、C4H9アルキル、C6H13アルキル、(1R,2S,5S)−5−メチルシクロペンタ−3−エン−1,2−ジオール及びC3H6−フェニル(該フェニルは、場合によりOH又はOCH3によって置換されている)から選択され、
Xは、O又はSであり、
Yは、C、N又はSである]で示される化合物、並びにその薬学的に許容し得る塩及び溶媒和物に関する。
R1は、H及びCH3から選択され、
R2は、H、C4H9アルキル、C6H13アルキル及びC3H6−フェニル(該フェニルは、場合によりOH又はOCH3によって置換されている)から選択され、
Xは、O又はSであり、
Yは、C、N又はSである。
本発明はまた、哺乳動物、特にヒトにおける多発性硬化症を処置する方法であって、該哺乳動物に、ある量の上記と同義の式(I)の化合物又はその薬学的に許容し得る塩若しくは溶媒和物を投与することを含む方法に関する。
膀胱の問題には
・ボツリヌス毒素(Botox)
・デスモプレシン(Desmospray、Desmotabs)
・オキシブチニン(Ditropan、Lyrinel)
・トルテロジン(Detrusitol)
鬱病には
・アミトリプチリン(Triptafen)
・フルオキセチン(Prozac)
・イミプラミン(Tofranil)
・パロキセチン(Seroxat)
勃起不全には
・アルプロスタジル(Caverject、MUSE、Viridal Duo)
・クエン酸シルデナフィル(Viagra)
・タダラフィル(Cialis)
・バルデナフィル(Levitra)
疲労には
・アマンタジン(Lysovir、Symmetrel)
・モダフィニル(Provigil)
視神経炎には
・ステロイド
疼痛には
・アミトリプチリン(Triptafen)
・カルバマゼピン(Tegretol)
・ガバペンチン(Neurontin)
・イブプロフェン
・イミプラミン(Tofranil)
・ラモトリジン(Lamictal)
・フェニトイン(Epanutim)
・プレガバリン(Lyrica)
歩行の問題には
・ファムプリジン(Fampyra)
情動調節障害には
・Nuedexta
痙性及び痙攣には
・バクロフェン(Lioresal)
・ボツリヌス毒素(Botox)
・カルバマゼピン(Tegretol)
・クロナゼパム(Rivotril)
・ダントロレン(Dantrium)
・ジアゼパム(Valium)
・ガバペンチン(Neurontin)
・フェノール
・テトラヒドロカンナビノール及びカンナビジオール(Sativex)
・チザニジン(Zanaflex)
振戦には
・クロナゼパム(Rivotril)
・視床切除術
三叉神経痛には
・カルバマゼピン(Tegretol)
・ガバペンチン(Neurontin)
・オクスカルバゼピン(Trileptal)
・フェニトイン(Epanutim)
・プレガバリン(Lyrica)
本発明における使用に適した種々の分子の合成法を以下に記載する。
撹拌棒を含む50cm3丸底フラスコに、2−アミノ−3H−ピロロ[2,3−d]ピリミジン−4(7H)−オン(2.00g、13.33mmol)を仕込んだ。フラスコにセプタムを取り付け、Ar雰囲気下に置いた。新たに蒸留したピリジン(20.00cm3)をシリンジで加え、生じた懸濁液を氷上で冷却した。この溶液をこの温度で平衡にさせ(約5分)、次いで塩化オクタノイル(6.80cm3、39.99mmol)を滴下した。生じた懸濁液を85℃で30分間加熱した。室温に冷却後、6.5%エタノール性アンモニア(60cm3)を加えて、生じた懸濁液を室温で一晩撹拌した。生成物の沈殿物を真空濾過により取り出して、エタノール、続いてジエチルエーテルで洗浄することにより、純粋な所望の生成物(2.56g、70%)を黄色の固体として得た、融点>300℃(分解)。Akimoto et al. 1986及びAkimoto et al. 1988に基づく手順。
δH (400 MHz, DMSO-d6): 0.86 (3H, t, J 5.1), 1.26 (8H, m), 1.58 (2H, 見かけ 5重項), 2.01 (1H, br s, NH), 2.43 (2H, t, J 5.1), 6.40 (1H, d, J 2.0), 7.01 (1H, d, J 2.0), 11.43 (1H, br s, NH), 11.67 (1H, br s, NH)
HRMS (m/z ESI-):実測値: 275.1517 ([M-H]- C14H19N4O2;要求値: 275.1508)
撹拌棒を含む50cm3反応容器に、2−オクタノイルアミノ−ピロロ[2,3−d]ピリミジン−4−オン(1.00g、3.60mmol)、ジベンジルアミン(2.00cm3、10.80mmol)、ホルマリン(349.00μL、12.60mmol)及び80%水性酢酸(36cm3)を仕込んだ。生じた懸濁液を60℃で20時間加熱し、室温に冷却し、0.5M HCl(36cm3)で希釈して室温で30分間撹拌した。この混合物を濃アンモニア水溶液(36cm3)で中和してクロロホルム(3×50cm3)で抽出した。有機抽出物を合わせ、乾燥させ(MgSO4)て蒸発乾固した。粗残渣をカラムクロマトグラフィー(9:1のジクロロメタン−MeOH〜7:3のジクロロメタン−MeOH)により精製することによって、所望の化合物(1.45g、84%)を黄色の粉末として得た、融点>300℃(分解)。Akimoto et al. 1986及びAkimoto et al. 1988に基づく手順。
δH (400 MHz, DMSO-d6): 0.86 (3H, t, J 7.1), 1.25 (8H, m), 1.57 (2H, m) 2.42 (2H, t, J 7.1), 3.57 (4H, s), 3.76 (2H, s), 6.88 (1H, s), 7.23 (2H, t, J 7.3), 7.31 (4H, 見かけ t), 7.41 (4H, d, J 7.3), 11.34 (1H, s, NH), 11.57 (1H, s, NH), 11.68 (1H, s, NH)
HRMS (m/z ESI+):実測値: 486.2863 ([M+H]+ C29H36N5O2;要求値: 486.2869)
撹拌棒を含む大きなカルーセル管に、2−オクタノイルアミノ−5−(((ジベンジル)アミノ)メチル)−ピロロ[2,3−d]ピリミジン−4−オン(100.0mg、0.21mmol)、3−フェニルプロピルアミン(146.00μL、1.03mmol)及び1:1のTHF−メタノール(2.00cm3)を仕込んだ。この懸濁液を脱気して反応容器を密封した。懸濁液を75℃で24時間加熱し、室温に冷却して、5M KOH(146.00μL)で処理して室温で65時間撹拌した。溶液を真空中で濃縮して、粗残渣をカラムクロマトグラフィー(9:0.9:0.1のジクロロメタン−MeOH−NH4OH)により精製した。微量不純物を除去するために、生じた固体をHPLC級ヘキサン、次にジエチルエーテルで洗浄した。これにより、所望の化合物(28mg、46%)を橙色の粉末として得た、融点>300℃(分解)。Akimoto et al. 1986及びAkimoto et al. 1988に基づく手順。
δH (600 MHz, DMSO-d6): 1.24 (1H, br s, NH), 1.66 (2H, 見かけ 5重項,), 1.91 (1H, s, NH), 2.44 (2H, t, J 6.9,), 2.57 (2H, t, J 6.9,), 3.59 (2H, s,), 6.15 (2H, br s,), 6.45 (1H, s,), 7.15 (1H, t, J 7.4,), 7.16 (3H, m), 7.25 (2H, 見かけ t,), 10.70 (1H, br s)
δC (600 MHz, DMSO-d6): 30.6, 32.9, 45.2, 47.5, 48.6, 79.2, 98.7 (q), 113.6 (q), 125.5, 128.2, 128.3, 142.3 (q), 152.2 (q), 160.5 (C=O)
nmax (フィルム)/cm-1: 697, 748, 749, 1080, 1420, 1596, 2927
HRMS (m/z ESI+): 実測値: 298.1662 ([M+H]+ C16H20N5O;要求値: 298.1668)
アルゴンの陽圧下で乾燥丸底フラスコ内で、無水THF(90mL)中のNaOMe(7.14g、0.13mol)の懸濁液を−5℃に冷却した。ギ酸メチル(9mL、0.15mol)をシリンジで1分間かけて滴下し、−5℃で20分間撹拌を続けた。次に、クロロアセトニトリル(8.33mL、0.13mol)を滴下漏斗により45分間かけて滴下した。混合物は白色から黄色に変わり、−5℃で更に2時間撹拌したところ、反応混合物は橙色になった。浴を取り外して、反応物が室温まで温まるに任せた。反応混合物のアリコートを1滴の濃HClで処理して、TLCにより分析すると、100% EtOAcで溶出する、Rf=0.45の所望の生成物の存在を示した。混合物を0℃に冷却して、濃HCl(12mL)を滴下すると、その間に混合反応物がサクランボ赤色になった。生じた懸濁液をセライトパッドで濾過して、セライトを濾液が無色になるまでEtOAcで洗浄した。集めた濾液を水浴で40℃以下の温度で減圧濃縮することにより、クロロ(ホルミル)アセトニトリル1を黒色の油状物として定量的収率で与えたが、これを更に精製することなく使用した。Brooks 2012に基づく手順。
δH (400 MHz, CDCl3) 9.38 (s, 1H).
δC NMR (400 MHz, DMSO-d6) δ 168.2, 126.6, 67.8.
2,4−ジアミノ−6−ヒドロキシピリミジン(3.00g、24mmol)を、ミリポア水(90mL)中の酢酸ナトリウム(6.4g、76mmol)の溶液に加えて50℃で1時間撹拌した。50℃のうちに、mQ水(44mL)中の粗クロロ(ホルミル)アセトニトリル(3.00g、32mmol)の溶液を滴下漏斗で滴下すると、その間に反応物はベージュ色になったが、50℃で18時間加熱を続け、その後、反応物を100℃まで3時間加熱した。反応混合物が室温まで冷却するに任せて、濾過により固体を取り出した。固体をEtOHに懸濁して、固体が溶解するまで5M KOH水溶液を加えた。活性炭を溶液に加えて、混合物を30分間撹拌した後、濾過により固体を除去した。濾液のpHを濃HCl水溶液でpH=6に調整すると、その間に沈殿物が形成され、これを濾過によって集めた。最終痕跡量の水を固体から除去するために、トルエン/メタノールの1/1混合物に溶解し、次に減圧で濃縮した。得られた固体をP2O5で乾燥することにより、所望の化合物(1.68g、9.6mmol、収率40%)をベージュ色の固体として与えた。Brooks 2012に基づく手順。
δH (400 MHz, DMSO-d6) δ 11.98 (br s, 1H) 10.74 (br s, 1H), 7.59 (s, 1H), 6.43 (s, 2H).
δC(100 MHz, DMSO-d6) δ 158.0, 154.3, 152.1, 128.2, 116.4, 99.2, 86.0.
HRMS (m/z ESI-): C7H5N5O [M-H]- 実測値 174.0415 要求値: 174.0416.
アルゴン雰囲気下で乾燥丸底フラスコ内で、塩化トリチル(1.20g、4.28mmol)を、無水ピリジン(29mL)中の2−アミノ−4,7−ジヒドロ−4−オキソ−3H−ピロロ[2,3−d]ピリミジン−5−カルボニトリル(0.50g、2.85mmol)の溶液に加えた。この混合反応物を90℃で48時間加熱した。反応混合物を減圧下で濃縮し、次いでシリカゲルに吸収させ、2% MeOHで開始し10%まで上昇する勾配のジクロロメタン/MeOHで溶出するシリカゲルのフラッシュクロマトグラフィーにより精製した。所望の化合物を褐色の固体(0.63g、1.5mmol、収率53%)として得た。
Olgen 2008に基づく手順。
δH (400 MHz, DMSO-d6) δ11.80 (br s, 1H); 10.64 (br s, 1H), 7.56 (s, 1H), 7.41(s, 1H), 7.29-7.28 (m, 12H), 7.23-7.17 (m, 3H), 5.73 (s, 1H).
HRMS (m/z ESI+): C26H18N5O [M-H]+ 実測値 416.1514 要求値: 416.1511.
HMDS(6mmol、1.3mL)を、丸底フラスコ内の無水トルエン(8mL)中の4,7−ジヒドロ−4−オキソ−2−[(トリフェニルメチル)アミノ]−3H−ピロロ[2,3−d]ピリミジン−5−カルボニトリル(1.30g、3mmol)と硫酸アンモニウム(397mg、0.3mmol)との混合物に加えた。還流冷却器を取り付けて、フラスコを還流温度で一晩加熱した。混合物を室温に冷却して、減圧下で濃縮した。陽圧のアルゴン下で、粗反応混合物を無水ジクロロメタン(8mL)に可溶化して−78℃に冷却した。この温度で、DiBAL−H(4.5mL、ジクロロメタン中1M、4.5mmol)を滴下した。2時間後、TLC(EtOAc 100%)により分析すると、少量の出発物質が残っていること分かった。そのためDiBAL−H溶液を更に2mL滴下した。1時間後、反応が完了し、H2O/AcOHの混合物(9/1、3.5mL)を−78℃で加えた。反応混合物がゆっくりと室温まで温まるに任せた。EtOAc/H2Oの混合物(1/1、300mL)を反応混合物に加えて、室温で2時間撹拌を続けた。層を分離し、有機層を食塩水で洗浄して、水層をEtOAcで抽出した。合わせた有機画分をMgSO4で乾燥させ、濾過して減圧で濃縮した。粗反応生成物を、EtOAcで溶出するシリカゲルのパッドを通して濾過することにより、黄色の固体(1.01g、2.38mmol、76%)を与えた。Brooks 2010及びBrooks 2012に基づく手順。
δH (400 MHz, DMSO-d6) 11.82 (s, 1H), 10.63 (s, 1H), 9.99 (s, 1H), 7.54 (s, 1H), 7.31-7.27 (m, 13H), 7.23-7.19 (m, 3H).
HRMS (m/z ESI-): C26H18N4O2[M-H]- 実測値 419.1508 要求値: 419.1508.
一般手順A:メタノール(5cm3)中のN−((4−オキソ−2−(トリチルアミノ)−4,7−ジヒドロ−3H−ピロロ[2,3−d]ピリミジン−5−イル)メチル)ホルムアミド(200.0mg、0.48mmol)及び硫酸ナトリウム(5.0mg)の懸濁液にアルゴン雰囲気下で3−フェニルプロピルアミン(74.00μL、0.52mmol)を加え、生じた懸濁液を室温で2時間撹拌した。次いで水素化ホウ素ナトリウム(55.00mg、1.43mmol)を加え、反応混合物を室温で更に1時間撹拌した。水(5cm3)を加えて、生じた懸濁液を10分間撹拌した後、ジクロロメタン(3×5cm3)で抽出した。合わせた有機層を乾燥させ(MgSO4)、真空中で濃縮することにより、粗生成物を生成し、これをフラッシュクロマトグラフィー(9:1のジクロロメタン−MeOH)により精製することによって、所望の化合物を白色の固体(210mg、41.8%)として生成した、融点>300℃(分解)。Brooks 2010及びBrooks 2012に基づく手順。
1H (400 MHz, DMSO-d6): 1.73 (2H, 5重項, J 7.8), 2.56 (4H, m), 3.74 (1H, s), 6.42 (1H, s, H-6), 7.19 (20H, m), 7.45 (1H, bs, NH), 10.78 (1H, bs, NH)
13C (400 MHz, DMSO-d6): 31.7, 32.8, 45.4, 47.8, 70.4 (q), 99.7 (q), 114.9, 117.6 (q), 125.9, 126.0, 126.9, 128.0, 128.6, 129.0, 142.6 (q), 145.4 (q), 150.0 (q), 150.4 (q), 159.7 (C=O)
HRMS (m/z - ESI+): 実測値: 540.2757 [M+H]+ C35H34N5O 要求値: 540.2765)
νmax/cm-1: 1542, 1611, 1670, 2868, 2951
一般手順B:撹拌棒を含む5cm3の反応容器に、5−((3−フェニルプロピルアミノ)メチル)−2−(トリチルアミノ)−3H−ピロロ[2,3−d]ピリミジン−4(7H)−オン(210.0mg、0.39mmol)及び1.25M メタノール性HCl(3cm3)を仕込んだ。生じた溶液を室温で16時間撹拌した。沈殿した生成物を真空濾過により取り出して、ジクロロメタンで洗浄することにより、所望の化合物を白色の粉末(84mg、68%)として得た、融点>300℃(分解)。Brooks 2010及びBrooks 2012に基づく手順。
δH (600 MHz, DMSO-d6): 1.90 (2H, 見かけ 5重項), 2.63 (2H, t, J 7.8), 2.90 (2H, m), 4.13 (2H, t, J 5.2), 6.57 (2H, bs), 6.80 (1H, d, J 2.3), 7.16 (3H, m), 7.26 (2H, t, J 7.0), 9.11 (2H, bs), 11.05 (1H, m, NH), 11.31 (1H, ブロード 2重項, NH)
δC (125 MHz, DMSO-d6): 27.6, 32.1, 42.9, 45.6, 48.9, 98.6, 108.7 (q), 117.9 (q),126.4, 128.6, 128.7, 140.9 (q), 152.9 (q), 160.5 (C=O)
HRMS (m/z ESI+): 実測値: 298.1662 (M+ C16H20N5O 要求値: 298.1664)
nmax (フィルム)/cm-1: 1456, 1625, 2443, 2713, 2756, 2873, 2933, 3184
N−((4−オキソ−2−(トリチルアミノ)−4,7−ジヒドロ−3H−ピロロ[2,3−d]ピリミジン−5−イル)メチル)ホルムアミド(200.00mg、0.48mmol)、n−ブチルアミン(95.00μL、0.95mmol)及びNaBH4(55mg、1.43mmol)を用いて一般手順Aのとおり調製することにより、所望の生成物を白色の粉末(200mg、88%)として生成した、融点>300℃(分解)。
δH(400 MHz, DMSO-d6): 0.84 (3H, t, J 7.3), 1.30 (2H, 見かけ 6重項), 1.51 (2H, 見かけ 5重項), 2.82 (2H, t, J 7.3), 4.01 (2H, s), 6.62 (1H, s), 7.24 (15H, m), 7.57 (1H, bs), 11.07 (1H, bs)
δC(400 MHz, DMSO-d6):13.9, 19.6, 28.0, 42.9, 46.0, , 70.6 (q), 99.4 (q), 108.9, 118.0 (q), 127.0, 128.1, 129.0, 145.2 (q), 150.5 (q), 150.6 (q), 160.3 (C=O)
nmax (フィルム)/cm-1: 1545, 1613, 1672, 2870, 2956
HRMS (m/z ESI+):実測値: 478.2600 ([M+H]+ C30H32N5O; 要求値: 478.2607)
5−((ブチルアミノ)メチル)−2−(トリチルアミノ)−3H−ピロロ[2,3−d]ピリミジン−4(7H)−オン(108mg、0.39mmol)及び1.25M メタノール性HCl(3cm3)を用いて一般手順Bのとおり調製することにより、所望の生成物を白色の粉末(72mg、67%)として生成した、融点>300℃(分解)。
δH (400 MHz, DMSO-d6): 0.86 (3H, t, J 7.4), 1.31 (2H, 見かけ 6重項), 1.57 (2H, 見かけ 5重項), 2.90 (2H, m), 4.12 (2H, t, J 5.3), 6.49 (2H, bs), 6.81 (1H, s), 9.01 (2H, bs), 10.98 (2H, bs), 11.29 (1H, bs)
δC (400 MHz, DMSO-d6): 18.7, 24.7, 32.7, 47.4, 50.6, 103.6 (q), 114.0, 123.2 (q), 153.3 (q), 157.6 (q), 164.7 (C=O)
HRMS (m/z ESI+): 実測値: 236.1518 (M+ C11H18N5O 要求値: 236.1511)
nmax (フィルム)/cm-1: 1456, 1625, 1668, 2443, 2713, 2756, 2873, 2933, 3184
N−((4−オキソ−2−(トリチルアミノ)−4,7−ジヒドロ−3H−ピロロ[2,3−d]ピリミジン−5−イル)メチル)ホルムアミド(200.0mg、0.48mmol)、n−ヘキシルアミン(125.00μL、0.95mmol)及び水素化ホウ素ナトリウム(55mg、1.43mmol)を用いて一般手順Aのとおり調製することにより、所望の生成物を白色の粉末(200mg、83.0%)として生成した、融点>300℃(分解)。
δH(400 MHz, DMSO-d6): 0.82 (3H, t, J 7.4), 1.20 (6H, m), 1.34 (2H, 見かけ 5重項), 2.40 (2H, t, J 7.4), 3.60 (2H, s), 6.30 (1H, s), 7.23 (15H, m), 7.37 (1H, bs), 10.62 (1H, bs)
δC(400 MHz, DMSO-d6):14.4, 22.5, 26.8, 31.6, 29.6, 45.2, 48.3, 70.4 (q), 99.7 (q), 115.2, 116.7 (q), 127.0, 128.1, 129.0, 145.4 (q), 150.1 (q), 150.5 (q), 159.7 (C=O)
nmax (フィルム)/cm-1: 1552, 1648, 1734, 2856, 2928
HRMS (m/z ESI-):実測値: 504.2769 ([M-H]- C32H34N5O; 要求値: 504.2763)
5−((ヘキシルアミノ)メチル)−2−(トリチルアミノ)−3H−ピロロ[2,3−d]ピリミジン−4(7H)−オン(190mg、0.39mmol)及び1.25M メタノール性HCl(3cm3)を用いて一般手順Bのとおり調製することにより、所望の生成物を白色の粉末(70mg、64.8%)として生成した、融点>300℃。
δH (400 MHz, DMSO-d6): 0.83 (3H, t, J 7.2), 1.25 (6H, m), 1.59 (2H, 見かけ 6重項, J 7.2), 2.87 (2H, m), 4.11 (2H, t, J 5.3), 6.71 (2H, bs), 6.84 (1H, d, J 3.6), 9.11 (2H, bs), 11.25 (1H, bs), 11.46 (1H, bs)
δC (400 MHz, DMSO-d6): 14.3, 22.3, 25.8, 25.9, 31.1, 42.6, 46.1, 98.9 (q), 109.3 (q), 118.5, 148.1 (q), 152.8 (q), 159.8 (C=O)
nmax (フィルム)/cm-1:1578, 1625, 1669, 2429, 2712, 2861, 2930, 2957, 3266
HRMS (m/z ESI+): 実測値: 264.1830 ([M+H]+ C13H22N5O 要求値: 264.1824)
H. Akimoto et al., J. Med. Chem., 1986, 29, 1749-1753.
S. Olgen et al., Arch. Pharm. Chem. Life Sci., 2008, 341, 113 - 120.
A.F. Brooks et al., Tetrahedron Lett., 2010, 51, 4163-4165.
A.F. Brooks PhD Thesis “Synthesis of Tritium Labeled Queuine, PreQ1 and Related Azide Probes Toward Examining the Prevalence of Queuine” University of Michigan, 2012.
Claims (17)
- Xが、Oである、請求項1記載の式(I)の化合物。
- Yが、C又はNである、前記請求項のいずれか一項記載の式(I)の化合物。
- Yが、Nである、前記請求項のいずれか一項記載の式(I)の化合物。
- R1が、Hである、前記請求項のいずれか一項記載の式(I)の化合物。
- R2が、C4H9アルキル、C6H13アルキル及びC3H6−フェニルから選択される、前記請求項のいずれか一項記載の式(I)の化合物。
- R2が、C3H6−フェニルである、前記請求項のいずれか一項記載の式(I)の化合物。
- 請求項1記載の式(I)の化合物であって、
Xが、Oであり、
Yが、Nであり、
R1が、Hであり;そして
R2が、C4H9アルキル、C6H13アルキル及びC3H6−フェニルから選択される、化合物。 - R2が、C3H6−フェニルである、請求項8記載の式(I)の化合物。
- 請求項10記載の使用であって、
R1が、H及びCH3から選択され、
R2が、H、C4H9アルキル、C6H13アルキル及びC3H6−フェニル(該フェニルは、場合によりOH又はOCH3によって置換されている)から選択され、
Xが、O又はSであり、
Yが、C、N又はSである、使用、並びにその薬学的に許容し得る塩及び溶媒和物。 - 自己免疫疾患の処置に使用するための、請求項10〜11記載の式(I)の化合物。
- 自己免疫疾患が、多発性硬化症である、請求項12記載の使用。
- 哺乳動物における自己免疫疾患を処置する方法であって、該哺乳動物に、ある量の請求項10〜11記載の式(I)の化合物、又はその薬学的に許容し得る塩若しくは溶媒和物を投与することを含む方法。
- 追加の治療剤と組合せた、請求項10〜11記載の式(I)の化合物。
- 治療剤が、患者の多発性硬化症損傷の影響の処置用の医薬品である、請求項15記載の組合せ。
- 前記請求項のいずれか一項記載の式(I)の化合物及び薬学的に許容し得る担体又は希釈剤を含む組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1417163.1A GB201417163D0 (en) | 2014-09-29 | 2014-09-29 | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases |
GB1417163.1 | 2014-09-29 | ||
PCT/EP2015/072486 WO2016050804A1 (en) | 2014-09-29 | 2015-09-29 | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017528510A true JP2017528510A (ja) | 2017-09-28 |
JP6679581B2 JP6679581B2 (ja) | 2020-04-15 |
Family
ID=51901285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017516829A Active JP6679581B2 (ja) | 2014-09-29 | 2015-09-29 | 自己免疫疾患の処置に有用な置換ピリミジン誘導体 |
Country Status (8)
Country | Link |
---|---|
US (2) | US10793572B2 (ja) |
EP (1) | EP3201198B1 (ja) |
JP (1) | JP6679581B2 (ja) |
AU (1) | AU2015326987B2 (ja) |
CA (1) | CA2962863C (ja) |
ES (1) | ES2825700T3 (ja) |
GB (1) | GB201417163D0 (ja) |
WO (1) | WO2016050804A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021517124A (ja) * | 2018-03-07 | 2021-07-15 | エーエムエーバイオティクス | アルツハイマー病を治療するための化合物 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2800917T3 (es) | 2016-08-30 | 2021-01-05 | Amabiotics | Compuestos para tratar enfermedades asociadas con una disfunción mitocondrial |
KR102133569B1 (ko) | 2018-06-28 | 2020-07-13 | 한국과학기술연구원 | 신규한 피롤로[2,3-d]피리미딘-4-온 유도체 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
EP4028014A1 (en) * | 2019-09-12 | 2022-07-20 | Stellate Therapeutics | Compounds for treating neurodegenerative diseases |
GB202011811D0 (en) | 2020-07-29 | 2020-09-09 | Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid | Compounds |
GB202011812D0 (en) | 2020-07-29 | 2020-09-09 | Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid | Compounds |
CN114163397A (zh) * | 2021-11-18 | 2022-03-11 | 安徽益多康尔医药科技有限公司 | 一种2-氨基噻唑-4-腈及其制备方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US119591A (en) * | 1871-10-03 | Improvement in locomotive-engines | ||
JPS5885889A (ja) * | 1981-11-18 | 1983-05-23 | Takeda Chem Ind Ltd | 新規7−デアザプリン誘導体 |
JPS58157790A (ja) * | 1982-03-16 | 1983-09-19 | Takeda Chem Ind Ltd | 7−デアザプリン誘導体およびその製造法 |
JPS5936615A (ja) | 1982-08-24 | 1984-02-28 | Takeda Chem Ind Ltd | 発がん予防剤 |
JPS6056980A (ja) | 1983-09-07 | 1985-04-02 | Takeda Chem Ind Ltd | 7−デアザプリン誘導体の製造法 |
DE3472258D1 (de) | 1983-03-17 | 1988-07-28 | Takeda Chemical Industries Ltd | Thiodeazapurine derivatives |
IE60433B1 (en) | 1986-08-26 | 1994-07-13 | Warner Lambert Co | Novel 9-deazaguanines |
US5061707A (en) | 1986-08-26 | 1991-10-29 | Warner-Lambert Company | 9-deazaguanines to treat psoriasis |
US5002950A (en) | 1986-10-24 | 1991-03-26 | Warner-Lambert Co. | 7-deazaguanines as immunomodulators |
CA1294960C (en) | 1986-10-24 | 1992-01-28 | Thomas C. Malone | 7-deazaguanines as immunomodulators |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5312900A (en) | 1991-04-08 | 1994-05-17 | La Jolla Cancer Research Foundation | 23K protein with binding specificity for queuine |
WO1996033703A2 (en) | 1995-04-25 | 1996-10-31 | Oridigm Corporation | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
EP1139773A4 (en) | 1998-12-15 | 2002-06-12 | Wrigley W M Jun Co | CONTROLLED DELIVERY OF ACTIVE SUBSTANCES FROM A CHEWING GUM COATING |
US20030078231A1 (en) | 2001-06-22 | 2003-04-24 | Wilburn Michael D. | Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties |
WO2009082247A1 (en) | 2007-12-21 | 2009-07-02 | Industrial Research Limited | Process for preparing immucillins having a methylene link |
US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US20110256130A1 (en) | 2008-12-01 | 2011-10-20 | Joshua Robert Schultz | Methods of treating inflammatory disorders |
WO2012150866A1 (en) | 2011-05-03 | 2012-11-08 | Industrial Research Limited | Phosphoribosyltransferase inhibitors and uses thereof |
-
2014
- 2014-09-29 GB GBGB1417163.1A patent/GB201417163D0/en not_active Ceased
-
2015
- 2015-09-29 EP EP15771947.7A patent/EP3201198B1/en active Active
- 2015-09-29 US US15/514,739 patent/US10793572B2/en active Active
- 2015-09-29 JP JP2017516829A patent/JP6679581B2/ja active Active
- 2015-09-29 WO PCT/EP2015/072486 patent/WO2016050804A1/en active Application Filing
- 2015-09-29 AU AU2015326987A patent/AU2015326987B2/en active Active
- 2015-09-29 ES ES15771947T patent/ES2825700T3/es active Active
- 2015-09-29 CA CA2962863A patent/CA2962863C/en active Active
-
2020
- 2020-08-27 US US17/004,097 patent/US11518765B2/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021517124A (ja) * | 2018-03-07 | 2021-07-15 | エーエムエーバイオティクス | アルツハイマー病を治療するための化合物 |
Also Published As
Publication number | Publication date |
---|---|
AU2015326987B2 (en) | 2020-05-14 |
AU2015326987A1 (en) | 2017-04-27 |
US10793572B2 (en) | 2020-10-06 |
ES2825700T3 (es) | 2021-05-17 |
US20170240553A1 (en) | 2017-08-24 |
JP6679581B2 (ja) | 2020-04-15 |
GB201417163D0 (en) | 2014-11-12 |
NZ730806A (en) | 2020-12-18 |
CA2962863A1 (en) | 2016-04-07 |
US20210024529A1 (en) | 2021-01-28 |
EP3201198A1 (en) | 2017-08-09 |
CA2962863C (en) | 2023-08-29 |
US11518765B2 (en) | 2022-12-06 |
WO2016050804A1 (en) | 2016-04-07 |
EP3201198B1 (en) | 2020-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11518765B2 (en) | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases | |
JP7345182B2 (ja) | 自己免疫疾患の処置 | |
US9790191B2 (en) | Substituted acylaminopyrimidines as inducers of alpha interferon production | |
JP5844354B2 (ja) | ヒドロキシピリドン誘導体、その医薬組成物、及び増殖性疾患治療のためのその治療的使用 | |
CN107001378A (zh) | 吡咯并嘧啶化合物 | |
TW202019887A (zh) | 酚系trpv1促效劑之聚乙二醇化前藥 | |
JP2001526275A (ja) | 中枢神経系障害の治療のためのトリアジン化合物 | |
ITFI20100001A1 (it) | Composti ad efficacia sia analgesica che antiperalgesica. | |
AU2021250904B2 (en) | Pyridinethiones, pharmaceutical compositions thereof, and their therapeutic use for treating a proliferative, inflammatory, neurodegenerative, or immune-mediated disease | |
NZ730806B2 (en) | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases | |
CN113603689B (zh) | 多环吡啶酮化合物及其药物组合物和用途 | |
CN116783197A (zh) | 化合物 | |
NZ730757B2 (en) | Treatments for autoimmune diseases | |
CN112694439A (zh) | 苯基丙烯酰胺基喹啉类衍生物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180928 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190613 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190618 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190905 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191106 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191210 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200218 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200318 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6679581 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |